ADAG
Adagene Inc.
Adagene (ADAG) Q2 2026 earnings
Published Aug 12, 2026
AI summary
- Revenue $1.62M, up from $0 a year ago.
- GAAP EPS −$0.23, unchanged from −$0.23 a year ago.
- Adagene reported revenue of $1.6 million for the first half of 2026, compared to no revenue in the prior year period.
- The company recorded a net loss of $16.4 million for the six-month period, up from $13.5 million a year ago.
- Cash and cash equivalents reached $127.9 million, providing a cash runway that extends into late 2028.
Results vs analyst consensus
Revenue
Reported
$1.62M
Consensus not captured before release
EPS · GAAP
Reported · GAAP diluted EPS
−$0.23
Consensus basis not comparable
Prior year: −$0.23
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is currently in a clinical-stage development phase and has not yet achieved consistent profitability.
- Financial results include non-cash share-based compensation expenses and changes in the fair value of warrant liabilities.
Read original report
Source: Adagene Inc. press release · SEC Form 6-K exhibit 99.1